Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

297 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PIP4K2C inhibition reverses autophagic flux impairment induced by SARS-CoV-2.
Karim M, Mishra M, Lo CW, Saul S, Cagirici HB, Tran DHN, Agrawal A, Ghita L, Ojha A, East MP, Gammeltoft KA, Sahoo MK, Johnson GL, Das S, Jochmans D, Cohen CA, Gottwein J, Dye J, Neff N, Pinsky BA, Laitinen T, Pantsar T, Poso A, Zanini F, Jonghe S, Asquith CRM, Einav S. Karim M, et al. Among authors: poso a. bioRxiv [Preprint]. 2024 Apr 17:2024.04.15.589676. doi: 10.1101/2024.04.15.589676. bioRxiv. 2024. PMID: 38659941 Free PMC article. Preprint.
Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships.
Asquith CRM, East MP, Laitinen T, Alamillo-Ferrer C, Hartikainen E, Wells CI, Axtman AD, Drewry DH, Tizzard GJ, Poso A, Willson TM, Johnson GL. Asquith CRM, et al. Among authors: poso a. Eur J Med Chem. 2024 May 5;271:116357. doi: 10.1016/j.ejmech.2024.116357. Epub 2024 Apr 2. Eur J Med Chem. 2024. PMID: 38636130 Free article.
Correction to "Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity".
Flury P, Breidenbach J, Krüger N, Voget R, Schäkel L, Si Y, Krasniqi V, Calistri S, Olfert M, Sylvester K, Rocha C, Ditzinger R, Rasch A, Pöhlmann S, Kronenberger T, Poso A, Rox K, Laufer SA, Müller CE, Gütschow M, Pillaiyar T. Flury P, et al. Among authors: poso a. ACS Pharmacol Transl Sci. 2024 Mar 6;7(4):1195-1196. doi: 10.1021/acsptsci.4c00095. eCollection 2024 Apr 12. ACS Pharmacol Transl Sci. 2024. PMID: 38633592 Free article.
Filling the Blank Space: Branched 4-Nonylphenol Isomers Are Responsible for Robust Constitutive Androstane Receptor (CAR) Activation by Nonylphenol.
Rashidian A, Dušek J, Drastik M, Smutná L, Fritsche K, Braeuning A, Pijnenburg D, van Beuningen R, Honkakoski P, Poso A, Kronenberger T, Pavek P. Rashidian A, et al. Among authors: poso a. Environ Sci Technol. 2024 Apr 23;58(16):6913-6923. doi: 10.1021/acs.est.3c10096. Epub 2024 Apr 9. Environ Sci Technol. 2024. PMID: 38593436
First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure.
Zwirner S, Abu Rmilah AA, Klotz S, Pfaffenroth B, Kloevekorn P, Moschopoulou AA, Schuette S, Haag M, Selig R, Li K, Zhou W, Nelson E, Poso A, Chen H, Amiot B, Jia Y, Minshew A, Michalak G, Cui W, Rist E, Longerich T, Jung B, Felgendreff P, Trompak O, Premsrirut PK, Gries K, Muerdter TE, Heinkele G, Wuestefeld T, Shapiro D, Weissbach M, Koenigsrainer A, Sipos B, Ab E, Zacarias MO, Theisgen S, Gruenheit N, Biskup S, Schwab M, Albrecht W, Laufer S, Nyberg S, Zender L. Zwirner S, et al. Among authors: poso a. Cell. 2024 Mar 28;187(7):1666-1684.e26. doi: 10.1016/j.cell.2024.02.023. Epub 2024 Mar 14. Cell. 2024. PMID: 38490194 Free PMC article. Clinical Trial.
Development of Selective Pyrido[2,3-d]pyrimidin-7(8H)-one-Based Mammalian STE20-Like (MST3/4) Kinase Inhibitors.
Rak M, Menge A, Tesch R, Berger LM, Balourdas DI, Shevchenko E, Krämer A, Elson L, Berger BT, Abdi I, Wahl LM, Poso A, Kaiser A, Hanke T, Kronenberger T, Joerger AC, Müller S, Knapp S. Rak M, et al. Among authors: poso a. J Med Chem. 2024 Mar 14;67(5):3813-3842. doi: 10.1021/acs.jmedchem.3c02217. Epub 2024 Feb 29. J Med Chem. 2024. PMID: 38422480
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors.
Wittlinger F, Ogboo BC, Shevchenko E, Damghani T, Pham CD, Schaeffner IK, Oligny BT, Chitnis SP, Beyett TS, Rasch A, Buckley B, Urul DA, Shaurova T, May EW, Schaefer EM, Eck MJ, Hershberger PA, Poso A, Laufer SA, Heppner DE. Wittlinger F, et al. Among authors: poso a. Commun Chem. 2024 Feb 20;7(1):38. doi: 10.1038/s42004-024-01108-3. Commun Chem. 2024. PMID: 38378740 Free PMC article.
Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity.
Flury P, Breidenbach J, Krüger N, Voget R, Schäkel L, Si Y, Krasniqi V, Calistri S, Olfert M, Sylvester K, Rocha C, Ditzinger R, Rasch A, Pöhlmann S, Kronenberger T, Poso A, Rox K, Laufer SA, Müller CE, Gütschow M, Pillaiyar T. Flury P, et al. Among authors: poso a. ACS Pharmacol Transl Sci. 2024 Jan 19;7(2):493-514. doi: 10.1021/acsptsci.3c00313. eCollection 2024 Feb 9. ACS Pharmacol Transl Sci. 2024. PMID: 38357286
The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma.
Spahn S, Kleinhenz F, Shevchenko E, Stahl A, Rasen Y, Geisler C, Ruhm K, Klaumuenzer M, Kronenberger T, Laufer SA, Sundberg-Malek H, Bui KC, Horger M, Biskup S, Schulze-Osthoff K, Templin M, Malek NP, Poso A, Bitzer M. Spahn S, et al. Among authors: poso a. Nat Commun. 2024 Feb 12;15(1):1287. doi: 10.1038/s41467-024-45247-6. Nat Commun. 2024. PMID: 38346946 Free PMC article.
Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome.
Bogacheva MS, Kuivanen S, Potdar S, Hassinen A, Huuskonen S, Pöhner I, Luck TJ, Turunen L, Feodoroff M, Szirovicza L, Savijoki K, Saarela J, Tammela P, Paavolainen L, Poso A, Varjosalo M, Kallioniemi O, Pietiäinen V, Vapalahti O. Bogacheva MS, et al. Among authors: poso a. Antiviral Res. 2024 Mar;223:105813. doi: 10.1016/j.antiviral.2024.105813. Epub 2024 Jan 24. Antiviral Res. 2024. PMID: 38272320 Free article.
297 results